Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: People with multiple sclerosis (pwMS) treated with ocrelizumab at our tertiary hospital during the COVID-19 pandemic were exposed to reduced dosing of 300 mg (RD) every 6 months, and also extended interval dosing (EID), due to concerns around infection risk and challenges attending hospital. We analysed clinical, MRI and laboratory outcomes to assess treatment effectiveness and safety compared with standard dosing (SD).
Methods: We collected data retrospectively on all people treated with ocrelizumab through our MS clinic from 01/01/2018 to 01/01/2024. Dates and dosage of ocrelizumab; expanded disability status score; clinical relapse; MRI brain and spine lesions; circulating B cells and immunoglobulin levels were collated. Annualised relapse risk and other parameters were calculated over time.
Results: A total of 113 pwMS were eligible for inclusion in the analysis. 76 pwMS received RD ocrelizumab, and 21 had EID. We found no significant difference in the clinical or radiological outcomes between the SD, RD or EID treatment regimens. During the follow-up period one person had a relapse just prior to EID at 9 months, and one had a relapse while on SD. B-cell repopulation prior to the subsequent dose occurred more frequently during EID compared with SD. There was a non-significant trend to higher immunoglobulin levels with RD and EID regimens compared with SD.
Conclusions: Reduced exposure to ocrelizumab in pwMS, through RD or EID, did not result in significant differences in clinical or radiological outcomes in our population. This real-world single centre study supports further prospective exploration of these strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2025.106641 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human myelinated brain organoids with integrated microglia as a model for myelin repair and remyelinating therapies.
Sci Transl Med
September 2025
Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Oligodendrocytes, the myelinating cells of the central nervous system (CNS), are essential for the formation of myelin sheaths and pivotal for maintaining axonal integrity and conduction. Disruption of these cells and the myelin sheaths they produce is a hallmark of demyelinating conditions like multiple sclerosis or those resulting from certain drug side effects, leading to profound neurological impairments. In this study, we created a human brain organoid comprising neurons, astrocytes, and myelinating oligodendrocytes.
View Article and Find Full Text PDFType I interferon limits central nervous system autoimmunity by modulating the microRNA-21-FOXO1 axis in pathogenic T helper 17 cells.
Sci Transl Med
September 2025
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
IFN-β, a type I interferon, has been used as a first-line therapy for patients with multiple sclerosis (MS) for more than 30 years; however, the cellular and molecular basis of its therapeutic efficacy remains unclear. Here, we first used experimental autoimmune encephalomyelitis (EAE), a mouse model for MS, to show that the therapeutic effects of IFN-β were associated with a down-regulation of microRNA-21 (miR-21) and pathogenic T17 (pT17) cells. In vitro experiments demonstrated that genetic knockout of miR-21 directly inhibited pathogenic T17 cell differentiation.
View Article and Find Full Text PDFWhat is the influence of fatigue, ALSFRS-R scores, cognitive status, and pain in individuals with Amyotrophic Lateral Sclerosis? A cross-sectional study.
Amyotroph Lateral Scler Frontotemporal Degener
September 2025
Department of Physiotherapy and Laboratory for Technological Innovation in Health, Federal University of Rio Grande do Norte, Natal, Brazil.
Fatigue remains a poorly understood symptom in individuals with ALS, and little is known about its associtation with other symptoms, including functional impairment, cognition, and pain. To identify the levels of fatigue, pain, ALSFRS-R, and cognition of a Brazilian group of individuals with ALS, in order to verify possible influences between these symptoms and fatigue. This is a cross-sectional study conducted with individuals with ALS who were recruited intentionally, using a non-probabilistic sampling method.
View Article and Find Full Text PDFParasagittal dural space and arachnoid granulations morphology in pre-clinical and early clinical multiple sclerosis.
Mult Scler
September 2025
Neuroimaging Unit, Neuroimmunology Division, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, VA Medical Center, TN Valley Healthcare System, Nashville, TN, USA.
Background: There is limited knowledge on the post-glymphatic structures such as the parasagittal dural (PSD) space and the arachnoid granulations (AGs) in multiple sclerosis (MS).
Objectives: To evaluate differences in volume and macromolecular content of PSD and AG between people with newly diagnosed MS (pwMS), clinically isolated syndrome (pwCIS), or radiologically isolated syndrome (pwRIS) and healthy controls (HCs) and their associations with clinical and radiological disease measures.
Methods: A total of 69 pwMS, pwCIS, pwRIS, and HCs underwent a 3.
Association Between Cannabis Use and Neuropsychiatric Disorders: A Two-sample Mendelian Randomization Study.
Alpha Psychiatry
August 2025
Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, 130021 Changchun, Jilin, China.
Background: The progressive legalization and widespread use of cannabis has led to its use as a treatment for certain neuropsychiatric disorders. Traditional epidemiological studies suggest that cannabis use has an effect on some neurocognitive aspects. However, it is unclear whether cannabis use is causally related to common neuropsychiatric disorders.
View Article and Find Full Text PDF